Abstract
Background:
Although cutaneous manifestations associated with thyroid dysfunction are classic, the potential for thyroid hormone or its antagonists to treat dermatological disease has not been explored with rigor. The predominant circulating thyroid hormone is the pro-hormone, thyroxine (T4). Skin, like many tissues, expresses thyroid hormone deiodinases to convert T4 to the active thyroid hormone, triiodothyronine (T3). Previously, we determined that T3 is necessary for optimal growth of keratinocytes and fibroblasts. The first hypothesis of this experiment was that the deiodinase inhibitor iopanoic acid (IOP) could inhibit cutaneous cell proliferation. The second hypothesis of this experiment was that the action of IOP could be attributed to its inhibition of conversion of T4 to T3. Although IOP is known to inhibit T4 to T3 conversion, the inhibition of cutaneous cell proliferation by IOP might conceivably result from other properties of IOP.
Methods:
In separate experiments, primary culture human keratinocytes and dermal fibroblasts were incubated overnight with IOP.
Results:
Proliferation was inhibited in a dose-dependent manner in both cell lines. Overnight incubation with T3 restored the proliferation but overnight incubation with T4 did not.
Conclusion:
The study is the first to demonstrate that IOP inhibits cutaneous cell proliferation and that supplemental T3 is sufficient to correct at least part of the inhibition caused by IOP. The data suggest that IOP decreases cutaneous cell proliferation by inhibition of intracellular T4 to T3 conversion. The data provide indirect evidence of the presence of type 1 or type 2 iodothyronine deiodinase activity in skin cells. The data support our previous hypothesis that T3 is necessary for normal cutaneous proliferation.